Cellular Biomedicine Group, Inc.
CBMG
CBMG was delisted on the 19th of February, 2021.
38 hedge funds and large institutions have $19.1M invested in Cellular Biomedicine Group, Inc. in 2016 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 15 increasing their positions, 9 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
67% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 9
6% more capital invested
Capital invested by funds: $18M → $19.1M (+$1.1M)
6% more funds holding
Funds holding: 36 → 38 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$728K |
| 2 |
Millennium Management
New York
|
+$614K |
| 3 |
Morgan Stanley
New York
|
+$461K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$329K |
| 5 |
Citigroup
New York
|
+$151K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Zurich Cantonal Bank
Zurich,
Switzerland
|
-$311K |
| 2 |
RhumbLine Advisers
Boston,
Massachusetts
|
-$34.5K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$30.1K |
| 4 |
SO
STRS Ohio
Columbus,
Ohio
|
-$21K |
| 5 |
TCIM
TIAA CREF Investment Management
New York
|
-$12.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIG
26
American International Group
New York
| $92K | -$254 | -19 | -0.3% |
|
|
BA
27
BlackRock Advisors
Wilmington,
Delaware
| $78K | +$5.42K | +405 | +7% |
|
28
Russell Investments Group
London,
United Kingdom
| $60K | +$60.3K | +4,504 | New |
|
29
Legal & General Group
London,
United Kingdom
| $54K | +$25.2K | +1,884 | +86% |
|
30
UBS Group
Zurich,
Switzerland
| $46K | +$1.87K | +140 | +4% |
|
31
Bank of America
Charlotte,
North Carolina
| $23K | +$14.8K | +1,106 | +167% |
|
32
BlackRock
New York
| $22K | -$1.46K | -109 | -6% |
|
33
Royal Bank of Canada
Toronto,
Ontario, Canada
| $10K | +$9.97K | +745 | New |
|
|
MAM
34
Meeder Asset Management
Dublin,
Ohio
| $5K | +$4.74K | +354 | New |
|
35
Creative Planning
Overland Park,
Kansas
| $4K | – | – | – |
|
36
BNP Paribas Financial Markets
Paris,
France
| $3.04K | -$8.99K | -672 | -74% |
|
37
Barclays
London,
United Kingdom
| $2K | -$80 | -6 | -4% |
|
|
SO
38
STRS Ohio
Columbus,
Ohio
| – | -$21K | -1,500 | Closed |
|
|
AIM
39
Acrospire Investment Management
Chicago,
Illinois
| – | -$4K | -300 | Closed |
|
CBMG Hedge Fund Activity: Q4 2016 in Review
38 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Cellular Biomedicine Group, Inc. (CBMG) for Q4 2016, worth a combined $19.1M — up 6.1% from $18M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CBMG positions and 2 closed out — a net gain of 3 holders — while 15 added to existing stakes and 9 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $728K. The largest seller was Zurich Cantonal Bank, cutting an estimated $311K.
- 38 institutional investors held Cellular Biomedicine Group, Inc. (CBMG) as of Q4 2016, up from 36 in Q3 2016.
- Funds reported $19.1M of Cellular Biomedicine Group, Inc. stock for Q4 2016, up 6.1% quarter-over-quarter.
- 5 funds opened new Cellular Biomedicine Group, Inc. positions in Q4 2016 and 2 closed out, a net change of +3 holders.
- The largest Cellular Biomedicine Group, Inc. buyer in Q4 2016 was BlackRock Fund Advisors, an estimated $728K added.
- The largest Cellular Biomedicine Group, Inc. seller in Q4 2016 was Zurich Cantonal Bank, an estimated $311K sold.
Based on aggregated 13F filings for Q4 2016.